Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,484 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Scheduling Clear all

Conditions: Post Operative Pain
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Substance Use Disorders
Interventions: IntACT, Usual Care; Behavioral
Lead sponsor: Michael Incze; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Premature Neonates
Interventions: Conservative weaning, Aggressive Weaning; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 1 Day and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Opioid Tapering
Interventions: Treatment as Usual (TAU), Telephonic Support (TS) Providers, DOTS Intervention; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, PR104, F-18-fluoromisonidazole; Biological · Drug · Other
Lead sponsor: Proacta, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Scottsdale, Arizona • San Antonio, Texas

Conditions: Prostate Cancer
Interventions: 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11; Drug · Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Boston, Massachusetts • Brooklyn, New York • New York, New York

Conditions: Breast Cancer
Interventions: Dasatinib and Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Cancer, Glioma
Interventions: 18F-FLT PET Scan; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression, Hiv
Interventions: upfront advice to walk, Supervised exercise; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Airway Morbidity, Intubation Complication, Tracheal Intubation Morbidity, Anesthesia Intubation Complication, Failed or Difficult Intubation, Sequela
Interventions: ZU-bend stylet, GlideScope, GlideRite stylet, Macintosh blade, Regular Double-lumen endobronchial tube (DLT) Stylet; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Education + Problem-Solving Training Self-Study, Education + Group Problem-Solving Training, Education + Individual Problem-Solving Training, Usual Care; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Intubation Complication, Intubation;Difficult
Interventions: Pneumaglide; Device
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Substance-Related Disorders, Mental Disorders
Interventions: RecoveryTrack - Extended Care (RT-E); Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Collingswood, New Jersey • Marlton, New Jersey • Philadelphia, Pennsylvania

Conditions: Breast Cancer, Mastectomy, Perfusion; Complications, Hemostasis
Interventions: PlasmaBlade 3.0S; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Invasive Breast Cancer, Post-mastectomy
Interventions: Radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Gynecologic Cancer
Interventions: Standard Post-Operative Counseling + FACT-G, PROM symptom tracker; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pregnancy
Interventions: Babyscripts Prenatal App, Placebo; Device
Lead sponsor: Andrew Meltzer; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Substance Use Disorder (SUD), Recovery
Interventions: EMA Only, EMI Only, EMA+EMI, Neither - RSAU; Other
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Normal, Illinois

Conditions: Myeloma
Interventions: Pomalidomide, Dexamethasone, Cyclophosphamide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: San Francisco, California • Tampa, Florida • New York, New York

Conditions: Brain Tumor, Recurrent, Brain Tumor, Refractory
Interventions: HER2-specific T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Continuous Glucose Sensor, Standard Care, CGS + Behavior Therapy; Device · Other · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 16 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Glaucoma
Interventions: Efficacy-patient navigator to improve follow-up adherence, Office-Based Usual Care; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 50 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced or Metastatic Solid Tumors
Interventions: DCSZ11, Pembrolizumab, Doxorubicin, Tebentafusp; Drug
Lead sponsor: DynamiCure Biotechnology; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Pirtobrutinib, Obinutuzumab; Drug
Lead sponsor: Inhye Ahn; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Scarborough, Maine • Boston, Massachusetts

Search by objective public record fields.

Effect of Gabapentin on Post-Operative Pain in Minimally Invasive Sacrocolpopexy

Feasibility of an Interdisciplinary Intervention to Improve Care Transitions for Hospitalized Patients With Substance Use Disorders

Weaning Thermoregulatory Support in Preterm Neonates

Opioid Tapering After Hospital Discharge: Testing an Intervention to Improve Post-operative Opioid Prescribing

PR104 and G-CSF in Treating Patients With Solid Tumors

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Image-Guided Stereotactic Biopsy of High Grade Gliomas

Supervised Treadmill Intervention to Reduce Inflammation and Depression Through Exercise in HIV: The STRIDE Pilot Study

Comparison of Double Lumen Tube Placement Techniques

Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes

Novel Airway Device to Aid Endotracheal Intubations

Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients

Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer

Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging

Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study

Using Smartphones to Provide Recovery Support Services

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control

Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia